Cargando…
The CAIRO4 study: the role of surgery of the primary tumour with few or absent symptoms in patients with synchronous unresectable metastases of colorectal cancer – a randomized phase III study of the Dutch Colorectal Cancer Group (DCCG)
BACKGROUND: There is no consensus regarding resection of the primary tumour with few or absent symptoms in patients with synchronous unresectable metastatic colorectal cancer (CRC). A potential benefit of resection of the primary tumour is to prevent complications of the primary tumour in later stag...
Autores principales: | ’t Lam - Boer, Jorine, Mol, Linda, Verhoef, Cornelis, de Haan, Anton F J, Yilmaz, Mette, Punt, Cornelis J A, de Wilt, Johannes H W, Koopman, Miriam |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4196118/ https://www.ncbi.nlm.nih.gov/pubmed/25277170 http://dx.doi.org/10.1186/1471-2407-14-741 |
Ejemplares similares
-
Treatment strategies in colorectal cancer patients with initially unresectable liver-only metastases, a study protocol of the randomised phase 3 CAIRO5 study of the Dutch Colorectal Cancer Group (DCCG)
por: Huiskens, Joost, et al.
Publicado: (2015) -
Short-Term Outcomes of Secondary Liver Surgery for Initially Unresectable Colorectal Liver Metastases Following Modern Induction Systemic Therapy in the Dutch CAIRO5 Trial
por: Bolhuis, Karen, et al.
Publicado: (2021) -
Intersurgeon Variability in Local Treatment Planning for Patients with Initially Unresectable Colorectal Cancer Liver Metastases: Analysis of the Liver Expert Panel of the Dutch Colorectal Cancer Group
por: Bond, Marinde J. G., et al.
Publicado: (2023) -
Postoperative mortality risk assessment in colorectal cancer: development and validation of a clinical prediction model using data from the Dutch ColoRectal Audit
por: de Nes, Lindsey C. F., et al.
Publicado: (2022) -
Loss of skeletal muscle index and survival in patients with metastatic colorectal cancer: Secondary analysis of the phase 3 CAIRO3 trial
por: Kurk, Sophie A., et al.
Publicado: (2019)